JOINT COMMERCIALIZATION AGREEMENT by and between GENMAB A/S and SEAGEN INC. Dated as of October 19, 2020Joint Commercialization Agreement • March 29th, 2021 • Genmab a/S • Pharmaceutical preparations • New York
Contract Type FiledMarch 29th, 2021 Company Industry JurisdictionTHIS JOINT COMMERCIALIZATION AGREEMENT (this “Agreement”) is made as of October 19, 2020 (the “Effective Date”), by and between GENMAB A/S, a Danish corporation (“Genmab”), and SEAGEN INC. (f/k/a SEATTLE GENETICS, INC.), a Delaware corporation (“SGI”). Genmab and SGI are sometimes referred to herein, individually, as a “Party” and, collectively, as the “Parties.”
Standard Contracts
CONTENTSCollaboration and License Agreement • March 29th, 2021 • Genmab a/S • Pharmaceutical preparations
Contract Type FiledMarch 29th, 2021 Company Industry[*] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and is the type of information that we treat as private or confidential.